WB214

WB214 (compound 11) (97 nM-10 μM; 72 h) potently inhibits RS4;11 human acute leukemia cell proliferation with an IC₅₀ of 1.2 nM^[1].
WB214 (1.2 nM-1 μM; 1-12 h) induces time- and dose-dependent degradation of MDM2 (DC₅₀ = 4.1 nM) and p53 (DC₅₀ = 29 nM) in RS4;11 human acute leukemia cells^[1].
WB214 (100 nM; 6 h) mediated degradation of MDM2 and p53 in RS4;11 human acute leukemia cells depends on the CRBN E3 ligase and ubiquitin-proteasome system, with p53 degraded as a bystander due to its association with MDM2^[1].
WB214 (97 nM-10 μM; 0.5 h) does not bind to the p53 binding pocket of purified MDM2 protein^[1].
WB214 (100 nM) efficiently induces ternary complex formation between MDM2 and CRBN in RS4;11 human acute leukemia cells^[1].
WB214 (increasing concentrations; 15 min) potently induces dose-dependent formation of ternary complexes between purified CRBN/DDB1 and MDM2 proteins^[1].
WB214 (100 nM; 6 h) causes degradation of MDM2 and p53 that is abolished when co-treated with Lenalidomide (HY-A0003) or MG132 (HY-13259)^[1].
WB214 (1.2-nM; 6-12 h) induces dose-dependent degradation of GSPT1 (DC₅₀ = 0.64 nM) in RS4;11 human acute leukemia cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.